Ionis Pharmaceuticals (IONS)
(Delayed Data from NSDQ)
$61.17 USD
-0.15 (-0.24%)
Updated Sep 17, 2025 04:00 PM ET
After-Market: $61.17 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value A Growth A Momentum B VGM
Fundamental Charts
About Market Cap
As of the previous market close, Ionis Pharmaceuticals, Inc. has a market cap of $9.77B, which represents its share price of $61.32 multiplied by its outstanding shares number of 159.39M. As a mid-cap company, IONS's shareholders are generally exposed to less risk than shareholders of small-cap companies but more risk than large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
IONS 61.17 -0.15(-0.24%)
Will IONS be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for IONS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IONS
IONS Up on FDA's Breakthrough Tag for ION582 in Angelman Syndrome
IONS Hits 52-Week High on Tryngolza's Success in Lowering Triglyceride
IONS: What are Zacks experts saying now?
Zacks Private Portfolio Services
BioCryst Pharmaceuticals Before Q2 Earnings: How to Play the Stock
Ionis Beats on Q2 Earnings & Sales, Stock Up 5% on Raised '25 Outlook
Here's What Key Metrics Tell Us About Ionis Pharmaceuticals (IONS) Q2 Earnings
Other News for IONS
Is IONS ready to make a move? NR7 shows up after gaining 0.36%
Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (IONS), Eli Lilly & Co (LLY) and Revvity (RVTY)
Technical picture remains unchanged for IONS after it falls 3.23% on September 15
Insider Sell: Patrick O'Neil Sells 1,700 Shares of Ionis Pharmaceuticals Inc (IONS)
IONS falls 1.33% on September 12, leaving the technical picture intact